收费全文 | 141514篇 |
免费 | 13911篇 |
国内免费 | 8389篇 |
医药卫生 | 163814篇 |
2024年 | 389篇 |
2023年 | 1991篇 |
2022年 | 4209篇 |
2021年 | 7210篇 |
2020年 | 5250篇 |
2019年 | 4713篇 |
2018年 | 4937篇 |
2017年 | 4535篇 |
2016年 | 4316篇 |
2015年 | 6307篇 |
2014年 | 7803篇 |
2013年 | 7588篇 |
2012年 | 10633篇 |
2011年 | 11289篇 |
2010年 | 7912篇 |
2009年 | 6391篇 |
2008年 | 7706篇 |
2007年 | 7710篇 |
2006年 | 7010篇 |
2005年 | 6348篇 |
2004年 | 4960篇 |
2003年 | 4827篇 |
2002年 | 4107篇 |
2001年 | 3420篇 |
2000年 | 2947篇 |
1999年 | 2607篇 |
1998年 | 1652篇 |
1997年 | 1773篇 |
1996年 | 1249篇 |
1995年 | 1190篇 |
1994年 | 1083篇 |
1993年 | 762篇 |
1992年 | 966篇 |
1991年 | 884篇 |
1990年 | 789篇 |
1989年 | 726篇 |
1988年 | 651篇 |
1987年 | 554篇 |
1986年 | 524篇 |
1985年 | 424篇 |
1984年 | 369篇 |
1983年 | 302篇 |
1982年 | 268篇 |
1981年 | 229篇 |
1980年 | 196篇 |
1979年 | 198篇 |
1978年 | 192篇 |
1977年 | 210篇 |
1976年 | 191篇 |
1974年 | 154篇 |
Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献